

## Contact details to obtain placebos for inhaler devices

<u>Company</u>	<u>Email address for placebos</u>	<u>Devices (not drug names)</u>	<u>Brand name</u>
Astrazeneca	<a href="mailto:Victoria.granger@astrazeneca.com">Victoria.granger@astrazeneca.com</a> <a href="mailto:Johan.jooste@astrazeneca.com">Johan.jooste@astrazeneca.com</a> 07384 239327	Turbohaler	Symbicort, Pulmicort etc.
		Genuair	Eklira, Duaklir
Boehringer-Ingelheim	<a href="mailto:lindsey.wright@boehringer-ingelheim.com">lindsey.wright@boehringer-ingelheim.com</a>	Handihaler	Tiotropium
		Respimat	Spiriva, Spiolto, Striverdi
Chiesi	<a href="mailto:Medinfo.uk@chiesi.com">Medinfo.uk@chiesi.com</a>	pMDI	Fostair, Trimbaw
		Nexthaler	Fostair
GlaxoSmithKline	<a href="mailto:customercontactuk@gsk.com">customercontactuk@gsk.com</a>	Evohaler	Seretide, Serevent etc.
		Accuhaler	Seretide, Serevent etc.
		Ellipta	Relvar, Anoro (LAMA/LABA), Trelegy
Napp	<a href="mailto:medicalinformationuk@napp.co.uk">medicalinformationuk@napp.co.uk</a>	pMDI	Flutiform
Novartis	<a href="mailto:medinfo.uk@novartis.com">medinfo.uk@novartis.com</a>	Breezhaler	Seebri, Ultibro
Orion	<a href="mailto:edina.hellyer@orionnshi.co.uk">edina.hellyer@orionnshi.co.uk</a>	Easyhaler	Various
Teva	<a href="mailto:marketingpc@tevauk.com">marketingpc@tevauk.com</a>	Autohaler	Qvar, Airomir
		Easi-Breathe	Salamol
		Spiromax	DuoResp, Aerivio
		Zonda	Braltus
Mylan	<a href="mailto:Alex.feeney@mylan.co.uk">Alex.feeney@mylan.co.uk</a>	pMDI	Sirdupla
Sandoz	<a href="mailto:george.samuel@sandoz.com">george.samuel@sandoz.com</a>	Forspiro	AirFluSal
		pMDI	AirFluSal
Clement Clarke	<a href="mailto:aphillips@clement-clarke.com">aphillips@clement-clarke.com</a>	Flo-tone	
		A2A spacer	
		Disposable spacers	

**Approved by:** East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

**Date:** April 2018 (Updated June 2019)

**Address:** c/o Canterbury and Coastal CCG, Council Offices, Military Road, Canterbury, CT1 1YW

**Contact:** T: 01227 791359 | E: [accg.eastkent.prescribing@nhs.net](mailto:accg.eastkent.prescribing@nhs.net)

## Inhaler technique

1. All patients should be asked to demonstrate their technique on every occasion to ensure effective technique
2. Placebos should be used to assess technique when first prescribed and when reviewing treatment. Company contact details are provide above
3. The required inspiratory flow rate for pressurised metred dose inhalers (pMDI) devices and Dry powder inhalers (DPIs) varies considerably. Inspiratory flow rate should be measured to ensure the patient is aware of the rate required for all prescribed devices.
4. Poor technique can lead to limited or no benefits but still expose the patient to side effects. Where adequate technique cannot be achieved, the benefit of on-going treatment should be discussed with the patient, as the impact of side effects may outweigh expected benefits.
5. There can be difficulties for patient when prescribed different devices for different drugs, where the technique per devices varies and particularly where different inspiratory flow rates are required. In this situation, patients should either be able to demonstrate the correct technique for each device or be prescribed devices which require similar inspiratory flow rates and techniques.
6. Please refer to the SPC for full prescribing details

**Approved by:** East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

**Date:** April 2018 (Updated June 2019)

**Address:** c/o Canterbury and Coastal CCG, Council Offices, Military Road, Canterbury, CT1 1YW

**Contact:** T: 01227 791359 | E: [accg.eastkent.prescribing@nhs.net](mailto:accg.eastkent.prescribing@nhs.net)